Ouabain Octahydrate

Modify Date: 2024-01-02 08:34:53

Ouabain Octahydrate Structure
Ouabain Octahydrate structure
Common Name Ouabain Octahydrate
CAS Number 11018-89-6 Molecular Weight 584.653
Density 1.5±0.1 g/cm3 Boiling Point 838.2±65.0 °C at 760 mmHg
Molecular Formula C29H60O20 Melting Point 260ºC
MSDS Chinese USA Flash Point 272.9±27.8 °C
Symbol GHS06 GHS08
GHS06, GHS08
Signal Word Danger

 Use of Ouabain Octahydrate


Ouabain Octahydrate is an inhibitor of Na+/K+-ATPase, used for the treatment of congestive heart failure.

 Names

Name Ouabain octahydrate
Synonym More Synonyms

 Ouabain Octahydrate Biological Activity

Description Ouabain Octahydrate is an inhibitor of Na+/K+-ATPase, used for the treatment of congestive heart failure.
Related Catalog
In Vitro Ouabain (100 μM) induces NLRP3 inflammasome activation and IL-1β release in macrophages. Ouabain-induced NLRP3 inflammasome activation is mediated through K+ efflux[1]. Ouabain (3 nM) alters the expression of EMT markers in NHK and ADPKD cells, and modifies cell-cell adhesion properties in ADPKD. Moreover, ouabain enhances migration of ADPKD cells, selectively modulates tight junctions, and modulates adherens junctions in ADPKD cells in a selective manner. Ouabain also activates TGFβ-Smad3 signaling, alters TER in ADPKD cells[2]. Ouabain (25, 50 or 100 nM) treatment significantly reduces cell proliferation and viability in Raji cells in a dose-dependent manner, with IC50 of 76.48±4.03 nM. Ouabain increases the number of apoptotic cells, induces autophagy, and upregulates Beclin-1 in Raji cells[4].
In Vivo Ouabain (3 mg/kg) significantly decreases cardiac contractile force with an enlarged LVESD when mice are primed with LPS. IL-1β deficiency attenuates ouabain-induced cardiac dysfunction and injury. IL-1β secreted by infiltrated macrophages contributes to ouabain-induced cardiac inflammation. Deficiency of NLRP3 and Casp1 attenuates ouabain-induced cardiac dysfunction and macrophage infiltration[1]. Ouabain (30 µg/kg, i.p.) modulates ABCB1 activity in thymocytes of Wistar rats and it has the same effect on Swiss mice at 300 µg/kg. After 14 days of ouabain treatment, the MAP of rats is significantly elevated[3].
Cell Assay Cell viability is determined using a Cell Counting Kit-8 assay. Briefly, 100 μL Raji cells (5×104/mL) are seeded in triplicate in a 96-well plate and treated with various concentrations of ouabain (400, 200, 100, 50, 25, 12.5, 6.25, 3.13, 1.56, 0.78 and 0.39 nM) for 48 h. Following the 48-h treatment, 10 μL CCK-8 reagent is added to each well, and the cells are incubated for an additional 3 h at 37°C. Optical density (OD) values at 450 nm are subsequently measured, and each ouabain concentration is assessed in triplicate. Raji cells cultured in medium without drug served as controls. Cell viability is calculated according to the following formula: Inhibition rate (%)=[1 − (OD450(sample) − OD450(blank))/(OD450(control) − OD450(blank))] × 100.
Animal Admin Mice[3] A total of 8 mice are used in the present study, 4 in the control group and 4 in the ouabain-treated group. Animals are maintained under standard laboratory conditions, with room temperature controlled (22°C), and subjected to 12 h light-dark cycles with ad libitum access to food and water. At 24 h subsequent to the intraperitoneal injection with 300 µg/kg of ouabain or PBS, the Swiss mice are sacrificed by barbiturate overdose (86 mg/kg intraperitoneal injection of pentobarbital). The mesenteric lymph nodes and thymi are immediately removed and softly dissociated. The remaining cells are washed in PBS and centrifuged at 200 × g. The pellet is suspended in ice-cold RPMI-1640 culture medium supplemented with 10% FBS until required for the activity assays. Rat[3] Male Wistar rats are treated with daily intraperitoneal injections of 30 µg/kg of ouabain or its vehicle, phosphate-buffered saline (PBS). A total of 20 rats are used, 12 for acute treatment (n=6 rats/group in ouabain and control groups) and 8 for chronic treatment (n=4 rats/group in ouabain and control groups). Animals are maintained under standard laboratory conditions, with room temperature controlled (22°C), and subjected to 12 h light-dark cycles with ad libitum access to food and water. Prior to the first injection at 24 h and 7 and 14 days subsequent to the injection, the rats have their blood pressure measured by a computerized tail-cuff method. The animals are sacrificed by barbiturate overdose (86 mg/kg intraperitoneal injection of pentobarbital) after 24 h (acute treatment) or 14 days (chronic treatment) of ouabain injections, and the mesenteric lymph nodes, thymi and blood are collected. Full excisions of thymi and partial excisions of mesentheric lymph nodes are performed, while blood samples are collected by caudal venous puncture prior to animals sacrifice.
References

[1]. Kobayashi M, et al. The cardiac glycoside ouabain activates NLRP3 inflammasomes and promotes cardiac inflammation and dysfunction. PLoS One. 2017 May 11;12(5):e0176676.

[2]. Venugopal J, et al. Ouabain promotes partial epithelial to mesenchymal transition (EMT) changes in human autosomal dominant polycystic kidney disease (ADPKD) cells. Exp Cell Res. 2017 Jun 15;355(2):142-152.

[3]. Lima DB, et al. Ouabain-induced alterations in ABCB1 of mesenteric lymph nodes and thymocytes of rats and mice. Oncol Lett. 2016 Dec;12(6):5275-5280.

[4]. Meng L, et al. Ouabain induces apoptosis and autophagy in Burkitt's lymphoma Raji cells. Biomed Pharmacother. 2016 Dec;84:1841-1848.

 Chemical & Physical Properties

Density 1.5±0.1 g/cm3
Boiling Point 838.2±65.0 °C at 760 mmHg
Melting Point 260ºC
Molecular Formula C29H60O20
Molecular Weight 584.653
Flash Point 272.9±27.8 °C
Exact Mass 584.283264
PSA 280.44000
LogP -1.64
Appearance of Characters powder | white
Vapour Pressure 0.0±0.6 mmHg at 25°C
Index of Refraction 1.655
Water Solubility H2O: 10 mg/mL cold | Soluble in water.

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
RN3850000
CHEMICAL NAME :
Ouabain octahydrate
CAS REGISTRY NUMBER :
11018-89-6
LAST UPDATED :
199409
DATA ITEMS CITED :
2
MOLECULAR FORMULA :
C29-H44-O12.8H2-O
MOLECULAR WEIGHT :
728.89
WISWESSER LINE NOTATION :
L E5 B666TJ A1Q CQ E1 IQ MQ QQ F- DT5OV EHJ& OO- BT6OTJ CQ DQ EQ F1 &QH 8

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1213 ug/kg
TOXIC EFFECTS :
Cardiac - arrhythmias (including changes in conduction)
REFERENCE :
JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 197,19,1976
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
3750 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
JOETD7 Journal of Ethnopharmacology. (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 1979- Volume(issue)/page/year: 39,161,1993

 Safety Information

Symbol GHS06 GHS08
GHS06, GHS08
Signal Word Danger
Hazard Statements H301 + H331-H373
Precautionary Statements Missing Phrase - N15.00950417-P260-P304 + P340 + P312-P403 + P233
Hazard Codes T: Toxic;
Risk Phrases R23/25
Safety Phrases S45
RIDADR UN 1544 6.1/PG 1
WGK Germany 3
RTECS RN3850000
Packaging Group III
Hazard Class 6.1(b)

 Articles72

More Articles
Crystals of Na(+)/K(+)-ATPase with bound cisplatin.

Biochem. Pharmacol. 92(3) , 494-8, (2014)

Cisplatin is the most widely used chemotherapeutics for cancer treatment, however, its administration is connected to inevitable adverse effects. Previous studies suggested that cisplatin is able to i...

A survey of detergents for the purification of stable, active human cystic fibrosis transmembrane conductance regulator (CFTR).

Biochim. Biophys. Acta 1838(11) , 2825-37, (2014)

Structural knowledge of the cystic fibrosis transmembrane conductance regulator (CFTR) requires developing methods to purify and stabilize this aggregation-prone membrane protein above 1mg/ml. Startin...

Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.

Biochem. Pharmacol. 90(4) , 367-78, (2014)

Cancer cells often become resistant to chemotherapy through a phenomenon known as multidrug resistance (MDR). Several factors are responsible for the development of MDR, preeminent among them being th...

 Synonyms

Card-20(22)-enolide, 3-[(6-deoxy-α-L-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxy-, (1β,3β,5β,11α)-
Ouabain a-L-rhamnoside
G-Strophanthin (JAN)
Strodival
4-[(1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-1,5,11,14-Tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-{[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2(5H)-furanone
Ouabain
Oubain
(1β,3β,5β,11α)-3-[(6-Deoxy-α-L-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxycard-20(22)-enolid
Gratibain
(1β,3β,5β,11α)-3-[(6-Deoxy-α-L-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxycard-20(22)-enolide
(1b,3b,5b,11a)-3-[(6-Deoxy-a-L-mannopyranosyl)oxy]-1,5,11,14,19-pentahydroxycard-20(22)-enolide
Astrobain
OUABAIN OCTAHYDRATE
Purostrophan
EINECS 211-139-3
g-Strophanthin Octahydrate
Card-20(22)-enolide, 3-((6-deoxy-α-L-mannopyranosyl)oxy)-1,5,11,14,19-pentahydroxy-, (1β,3β,5β,11α)-
g-Strophantoside
MFCD00003688
Acocantherin
Gratus strophanthin
STROPHOPERM
Top Suppliers:I want be here


Get all suppliers and price by the below link:

Ouabain Octahydrate suppliers


Price: $66/10mM*1mLinDMSO

Reference only. check more Ouabain Octahydrate price